These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 24395436)
1. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K; Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R; Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761 [TBL] [Abstract][Full Text] [Related]
3. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K; Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159 [TBL] [Abstract][Full Text] [Related]
4. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426 [TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F; Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654 [TBL] [Abstract][Full Text] [Related]
6. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
7. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis. Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286 [TBL] [Abstract][Full Text] [Related]
8. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948 [TBL] [Abstract][Full Text] [Related]
9. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519 [TBL] [Abstract][Full Text] [Related]
10. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697 [TBL] [Abstract][Full Text] [Related]
11. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Lennard L; Cartwright CS; Wade R; Vora A Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457 [TBL] [Abstract][Full Text] [Related]
12. Role of TPMT and ITPA variants in mercaptopurine disposition. Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964 [TBL] [Abstract][Full Text] [Related]
13. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306 [TBL] [Abstract][Full Text] [Related]
15. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828 [TBL] [Abstract][Full Text] [Related]
16. Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers. Nielsen SN; Eriksson F; Rosthoej S; Andersen MK; Forestier E; Hasle H; Hjalgrim LL; Aasberg A; Abrahamsson J; Heyman M; Jónsson ÓG; Pruunsild K; Vaitkeviciené GE; Vettenranta K; Schmiegelow K Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28500740 [TBL] [Abstract][Full Text] [Related]
17. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Schmiegelow K; Forestier E; Hellebostad M; Heyman M; Kristinsson J; Söderhäll S; Taskinen M; Leukemia; 2010 Feb; 24(2):345-54. PubMed ID: 20010622 [TBL] [Abstract][Full Text] [Related]
18. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia. Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254 [TBL] [Abstract][Full Text] [Related]
19. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related]
20. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Kapoor G; Sinha R; Naithani R; Chandgothia M Leuk Res; 2010 Aug; 34(8):1023-6. PubMed ID: 20153897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]